Stem-Cell Secretomes for Liver Repair: Mechanisms, Clinical Evidence, and Emerging Therapeutic Strategies

Abstract

Stem-cell secretomes, comprising cytokines, growth factors, extracellular vesicles, and microRNAs secreted by stem cells, have emerged as promising agents for liver repair. Rather than relying solely on cell engraftment, the paracrine effects of these bioactive molecules offer novel therapeutic avenues for acute and chronic liver diseases. This review synthesizes current evidence on secretome composition, mechanisms of action, clinical applications, and future directions. We highlight key clinical trials, summarize safety and efficacy data, and discuss guideline perspectives, providing a comprehensive resource for clinicians and researchers seeking to integrate stem-cell secretome therapies into liver disease management.

Introduction

Liver diseases, including acute liver failure, cirrhosis, and nonalcoholic fatty liver disease (NAFLD), represent major global health burdens with limited curative options apart from transplantation. Stem-cell-based interventions have gained attention in regenerative hepatology, yet challenges such as limited cell survival, immune rejection, and tumorigenic potential remain. Emerging evidence indicates that the beneficial effects of stem cells are largely mediated by their secretomes—complex mixtures of soluble factors with potent regenerative, immunomodulatory, and anti-fibrotic properties. Understanding the therapeutic potential and clinical translation of stem-cell secretomes is essential for advancing liver repair strategies.

Epidemiology / Disease Burden

Chronic liver diseases affect over 1.5 billion people worldwide and account for approximately 2 million deaths annually. Cirrhosis and hepatocellular carcinoma (HCC) are principal causes of liver-related mortality. Despite advances in antiviral therapies and metabolic disease management, the incidence of end-stage liver disease and liver failure is rising, driven by viral hepatitis, alcohol-related liver disease, and the increasing prevalence of NAFLD. Liver transplantation remains the only definitive cure for end-stage disease, but donor shortages and contraindications limit accessibility. Thus, there is a pressing need for alternative regenerative therapies.

Pathophysiology

Liver injury initiates a cascade involving hepatocyte death, inflammatory cell recruitment, and activation of hepatic stellate cells, leading to fibrosis and impaired regeneration. Endogenous hepatic progenitor cells can contribute to repair, but their capacity is insufficient in advanced disease. Stem-cell secretomes have been shown to modulate key pathophysiological processes by dampening inflammation, promoting hepatocyte proliferation, inhibiting apoptosis, and attenuating fibrogenic signaling. Mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) secrete a repertoire of trophic factors, including HGF, VEGF, IGF-1, and anti-inflammatory cytokines, along with exosomes containing regulatory microRNAs. These factors orchestrate a pro-regenerative microenvironment within the injured liver.

Risk Factors

The clinical utility of stem-cell secretomes is influenced by patient-specific factors such as the etiology and stage of liver disease, comorbidities, immune status, and prior treatments. Advanced fibrosis, persistent inflammation, and metabolic derangements can hinder regenerative responses. Additionally, risks associated with secretome therapy include immunogenicity, off-target effects, and the theoretical potential for tumor promotion, especially if secretome composition is not tightly controlled. Rigorous patient selection and safety monitoring are critical.

Clinical Features

Patients with end-stage liver disease present with jaundice, coagulopathy, hepatic encephalopathy, portal hypertension, and multisystem complications. The clinical heterogeneity necessitates individualized approaches to regenerative therapy. Early clinical studies of secretome-based interventions report improvements in serum transaminases, bilirubin, and synthetic function, alongside reduced fibrosis and enhanced quality of life. However, heterogeneity in administration protocols and outcome measures complicates direct comparison across studies.

Diagnosis

Diagnosis of liver disease is established using a combination of clinical, laboratory, and imaging findings. Biomarkers such as ALT, AST, albumin, INR, and imaging modalities including ultrasound, CT, and MRI assess disease severity and monitor therapeutic response. Emerging biomarkers, including cell-free DNA and exosomal microRNAs, may serve as pharmacodynamic indicators of secretome activity and treatment efficacy. Liver biopsy remains the gold standard for assessing histological response, although non-invasive fibrosis markers are increasingly utilized in clinical trials.

Treatment & Management

Conventional management of chronic liver disease focuses on removing etiological factors, managing complications, and providing supportive care. Regenerative interventions seek to restore hepatic architecture and function. Stem-cell secretomes can be delivered via intravenous infusion, intraportal injection, or local application, either as conditioned media, purified exosomes, or engineered vesicles. Preclinical models demonstrate reduced necrosis, enhanced regeneration, and attenuation of fibrosis following secretome administration. Clinical translation is underway, with early-phase trials supporting feasibility and safety, though large-scale efficacy data are pending.

Recent Advances / Emerging Therapies

Recent advances include the isolation and characterization of exosome-enriched secretome fractions, bioengineering of secretomes for targeted delivery, and the development of off-the-shelf allogeneic secretome products. Gene editing and preconditioning of stem cells can augment the therapeutic potency of secretomes. Phase I/II trials in patients with cirrhosis and acute-on-chronic liver failure report improvements in liver function and reduced inflammatory markers, with minimal adverse events. Ongoing studies are exploring combinatorial strategies, such as secretome therapy with antifibrotic agents or immunomodulators, to synergistically enhance repair.

Guideline Recommendations

Current international guidelines do not formally endorse stem-cell secretome therapies outside of research settings, emphasizing the need for robust, randomized controlled trials to establish efficacy and safety. Expert consensus highlights the potential of secretome-based approaches for selected patients with advanced liver disease not amenable to transplantation. Regulatory authorities require standardized production, comprehensive characterization, and rigorous quality control of secretome products. Clinicians are advised to enroll patients in clinical trials and adhere to evolving regulatory guidance.

Conclusion

Stem-cell secretomes represent a paradigm shift in liver regenerative medicine, offering multifaceted mechanisms to promote hepatic repair and modulate disease progression. While preclinical and early clinical evidence is encouraging, further research is essential to optimize secretome composition, delivery, and patient selection. Integration of secretome therapies into clinical practice will depend on the results of ongoing trials and the development of robust regulatory frameworks. Continued interdisciplinary collaboration will be critical to realizing the full therapeutic potential of stem-cell secretomes for liver repair.